Liliane Tenenbaum

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


56 publications

2024 | 2023 | 2021 | 2020 | 2019 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2005 | 2004 | 2003 | 2002 | 2000 | 1999 | 1996 | 1994 | 1993 | 1990 | 1988 | 1985 |
2024
 
Cell-to-cell transmitted alpha-synuclein recapitulates experimental Parkinson's disease.
Prymaczok N.C., De Francesco P.N., Mazzetti S., Humbert-Claude M., Tenenbaum L., Cappelletti G., Masliah E., Perello M., Riek R., Gerez J.A., 2024/01/06. NPJ Parkinson's disease, 10 (1) p. 10. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AA6B6F98A17F]
2023
Oxidative stress induced by sustained supraphysiological intrastriatal GDNF delivery is prevented by dose regulation.
Azevedo M.D., Prince N., Humbert-Claude M., Mesa-Infante V., Jeanneret C., Golzne V., De Matos K., Jamot B.B., Magara F., Gonzalez-Hernandez T. et al., 2023/12/14. Molecular therapy. Methods & clinical development, 31 p. 101106. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E58A2517FCE0]
18 kDa Translocator Protein TSPO Is a Mediator of Astrocyte Reactivity
Tournier Benjamin B., Bouteldja Farha, Amossé Quentin, Nicolaides Alekos, Duarte Azevedo Marcelo, Tenenbaum Liliane, Garibotto Valentina, Ceyzériat Kelly, Millet Philippe, 2023/08/29. ACS Omega, 8 (34) pp. 31225-31236. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2ED5ACD7E717]
2021
 
CDNF: An innovative actor in disease-modifying approaches for Parkinson's disease.
Tenenbaum L., 2021/09/01. Molecular therapy, 29 (9) pp. 2634-2636. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_57FB722FFDFB]
Selective targeting of striatal parvalbumin-expressing interneurons for transgene delivery.
Duarte Azevedo M., Sander S., Jeanneret C., Olfat S., Tenenbaum L., 2021/04/15. Journal of neuroscience methods, 354 p. 109105. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_780C1BCAFFB6]
2020
MMP9/RAGE pathway overactivation mediates redox dysregulation and neuroinflammation, leading to inhibitory/excitatory imbalance: a reverse translation study in schizophrenia patients.
Dwir D., Giangreco B., Xin L., Tenenbaum L., Cabungcal J.H., Steullet P., Goupil A., Cleusix M., Jenni R., Chtarto A. et al., 2020/11. Molecular psychiatry, 25 (11) pp. 2889-2904. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6531CBA55607]
 
Human Fetal Cell Therapy in Huntington's Disease: A Randomized, Multicenter, Phase II Trial
Bachoud-Lévi Anne-Catherine, Schramm Catherine, Remy Philippe, Aubin Ghislaine, Blond Serge, Bocket Laurence, Brugières Pierre, Calvas Fabienne, Calvier Elisabeth, Cassim François et al., 2020/08. Movement Disorders, 35 (8) pp. 1323-1335.
[DOI][WoS][Pmid][serval:BIB_8DE664B5FA78]
GDNF, A Neuron-Derived Factor Upregulated in Glial Cells during Disease.
Duarte Azevedo M., Sander S., Tenenbaum L., 2020/02/07. Journal of clinical medicine, 9 (2). Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_BCB65D4BAEEF]
2019
Combining Gene Transfer and Nonhuman Primates to Better Understand and Treat Parkinson's Disease.
Lasbleiz C., Mestre-Francés N., Devau G., Luquin M.R., Tenenbaum L., Kremer E.J., Verdier J.M., 2019. Frontiers in molecular neuroscience, 12 p. 10. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AE05ED755F21]
2017
 
Regulated viral BDNF delivery in combination with Schwann cells promotes axonal regeneration through capillary alginate hydrogels after spinal cord injury.
Liu S., Sandner B., Schackel T., Nicholson L., Chtarto A., Tenenbaum L., Puttagunta R., Müller R., Weidner N., Blesch A., 2017/09/15. Acta biomaterialia, 60 pp. 167-180. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0648A9F82B50]
Glial Cell Line-Derived Neurotrophic Factor Gene Delivery in Parkinson's Disease: A Delicate Balance between Neuroprotection, Trophic Effects, and Unwanted Compensatory Mechanisms.
Tenenbaum L., Humbert-Claude M., 2017. Frontiers in neuroanatomy, 11 p. 29. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_148F8283D322]
2016
Tollip, an early regulator of the acute inflammatory response in the substantia nigra.
Humbert-Claude M., Duc D., Dwir D., Thieren L., Sandström von Tobel J., Begka C., Legueux F., Velin D., Maillard M.H., Do K.Q. et al., 2016/12/07. Journal of neuroinflammation, 13 (1) p. 303. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_637444BCA5E2]
Effect of SOCS1 overexpression on RPE cell activation by proinflammatory cytokines.
Bazewicz M., Draganova D., Makhoul M., Chtarto A., Elmaleh V., Tenenbaum L., Caspers L., Bruyns C., Willermain F., 2016/09/06. Neuroscience letters, 630 pp. 209-215. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2D23E59D94BD]
A regulatable AAV vector mediating GDNF biological effects at clinically-approved sub-antimicrobial doxycycline doses.
Chtarto A., Humbert-Claude M., Bockstael O., Das A.T., Boutry S., Breger L.S., Klaver B., Melas C., Barroso-Chinea P., Gonzalez-Hernandez T. et al., 2016. Molecular Therapy. Methods and Clinical Development, 5 p. 16027. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AB62686BE882]
Long-term controlled GDNF over-expression reduces dopamine transporter activity without affecting tyrosine hydroxylase expression in the rat mesostriatal system.
Barroso-Chinea P., Cruz-Muros I., Afonso-Oramas D., Castro-Hernández J., Salas-Hernández J., Chtarto A., Luis-Ravelo D., Humbert-Claude M., Tenenbaum L., González-Hernández T., 2016. Neurobiology of Disease, 88 pp. 44-54. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_25E6F021B352]
Tet-On Systems For Doxycycline-inducible Gene Expression.
Das A.T., Tenenbaum L., Berkhout B., 2016. Current gene therapy, 16 (3) pp. 156-167. Peer-reviewed.
[URN][Pmid][serval:BIB_3BB90FF42FA1]
2015
Mild guanidinoacetate increase under partial guanidinoacetate methyltransferase deficiency strongly affects brain cell development.
Hanna-El-Daher L., Béard E., Henry H., Tenenbaum L., Braissant O., 2015. Neurobiology of Disease, 79 pp. 14-27. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_294E3C88D1F4]
2014
Intracisternal delivery of NFκB-inducible scAAV2/9 reveals locoregional neuroinflammation induced by systemic kainic acid treatment.
Bockstael O., Tenenbaum L., Dalkara D., Melas C., De Witte O., Levivier M., Chtarto A., 2014. Frontiers In Molecular Neuroscience, 7 p. 92.
[URN][DOI][WoS][Pmid][serval:BIB_648500CB71EC]
Manufacturing and characterization of a recombinant adeno-associated virus type 8 reference standard material.
Ayuso E., Blouin V., Lock M., McGorray S., Leon X., Alvira M.R., Auricchio A., Bucher S., Chtarto A., Clark K.R. et al., 2014. Human Gene Therapy, 25 (11) pp. 977-987. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3BB1F3A8DF53]
2013
A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting.
Chtarto A., Bockstael O., Tshibangu T., Dewitte O., Levivier M., Tenenbaum L., 2013. British Journal of Clinical Pharmacology, 76 (2) pp. 217-232. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BF66B3F58A82]
An adeno-associated virus-based intracellular sensor of pathological nuclear factor-κB activation for disease-inducible gene transfer.
Chtarto A., Bockstael O., Gebara E., Vermoesen K., Melas C., Pythoud C., Levivier M., De Witte O., Luthi-Carter R., Clinkers R. et al., 2013. PLoS One, 8 (1) pp. e53156.
[URN][DOI][WoS][Pmid][serval:BIB_B176D5FCC554]
Biosafety of Recombinant Adeno-associated Virus Vectors.
Dismuke D.J., Tenenbaum L., Samulski R.J., 2013. Current Gene Therapy, 13 (6) pp. 434-452.
[URN][WoS][Pmid][serval:BIB_7891F9516BD2]
2012
 
An adeno-associated virus-based intracellular sensor of pathological Nuclear Factor-kappaB activation for disease-inducible gene therapy.
Chtarto A., Vermoesen K., Gebara E., Bockstael O., Melas C., Levivier M., De Witte O., Luthi-Carter R., Clinkers R., Tenenbaum L., 2012. pp. A128-A129 dans ISSUU-ESGCT Conference 2012, European Society of Gene and Cell Therapy French Society for Cell and Gene Therapy Collaborative Congress, Human Gene Therapy.
[WoS][serval:BIB_704B5EA75905]
 
Rapid transgene expression in multiple precursor cell types of adult rat subventricular zone mediated by adeno-associated type 1 vectors.
Bockstael O., Melas C., Pythoud C., Levivier M., McCarty D., Samulski R.J., De Witte O., Tenenbaum L., 2012. Human Gene Therapy, 23 (7) pp. 742-753.
[DOI][WoS][Pmid][serval:BIB_9EED285EBC53]
 
Recombinant AAV Delivery to the Central Nervous System
Bockstael Olivier, Foust Kevin D., Kaspar Brian, Tenenbaum Liliane, 2012. pp. 159-177 dans Adeno-Associated Virus, Humana Press.
[DOI][WoS][Pmid][serval:BIB_38DBA13884EB]
2011
 
Development of a Liver-specific Tet-On Inducible System for AAV Vectors and Its Application in the Treatment of Liver Cancer.
Vanrell L., Di Scala M., Blanco L., Otano I., Gil-Farina I., Baldim V., Paneda A., Berraondo P., Beattie S.G., Chtarto A. et al., 2011/03. Molecular Therapy : the Journal of the American Society of Gene Therapy, 19 (7) pp. 1245-1253.
[DOI][WoS][Pmid][serval:BIB_EDB4C9AEEE2C]
 
Development of a successful antitumor therapeutic model combining in vivo dendritic cell vaccination with tumor irradiation and intratumoral GM-CSF delivery.
Driessens G., Nuttin L., Gras A., Maetens J., Mievis S., Schoore M., Velu T., Tenenbaum L., Préat V., Bruyns C., 2011. Cancer Immunology, Immunotherapy : Cii, 60 (2) pp. 273-281.
[DOI][WoS][Pmid][serval:BIB_EAC1414AE7F9]
2010
 
Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material.
Lock M., McGorray S., Auricchio A., Ayuso E., Beecham E.J., Blouin-Tavel V., Bosch F., Bose M., Byrne B.J., Caton T. et al., 2010. Human Gene Therapy, 21 (10) pp. 1273-1285.
[DOI][Pmid][serval:BIB_4A6226712A85]
2009
 
Reversible neurochemical changes mediated by delayed intrastriatal glial cell line-derived neurotrophic factor gene delivery in a partial Parkinson's disease rat model.
Yang X., Mertens B., Lehtonen E., Vercammen L., Bockstael O., Chtarto A., Levivier M., Brotchi J., Michotte Y., Baekelandt V. et al., 2009. Journal of Gene Medicine, 11 (10) pp. 899-912.
[DOI][Pmid][serval:BIB_8F63F8819274]
2008
Differential transgene expression profiles in rat brain, using rAAV2/1 vectors with tetracycline-inducible and cytomegalovirus promoters.
Bockstael O., Chtarto A., Wakkinen J., Yang X., Melas C., Levivier M., Brotchi J., Tenenbaum L., 2008. Human Gene Therapy, 19 (11) pp. 1293-1305. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_82A1C45B99C0]
Recombinant AAV viral vectors serotype 1, 2, and 5 mediate differential gene transfer efficiency in rat striatal fetal grafts.
Lubansu A., Abeloos L., Bockstael O., Lehtonen E., Blum D., Brotchi J., Levivier M., Tenenbaum L., 2008. Cell Transplantation, 16 (10) pp. 1013-1020.
[Pmid][serval:BIB_6AA2382470F2]
2007
 
Overexpression of mouse IsK protein fused to green fluorescent protein induces apoptosis of human astroglioma cells
Stathopoulos A., Melas C., Attali B., Blum D., Levivier M., Brotchi J., Velu T., Tenenbaum L., 2007/09. Neurological Research, 29 (6) pp. 628-31. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3F421C6854FB]
 
Controlled delivery of glial cell line-derived neurotrophic factor by a single tetracycline-inducible AAV vector.
Chtarto A., Yang X., Bockstael O., Melas C., Blum D., Lehtonen E., Abeloos L., Jaspar J.M., Levivier M., Brotchi J. et al., 2007. Experimental Neurology, 204 (1) pp. 387-399. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_188FEB5FD22E]
2005
 
Efficiency of adeno-associated virus type-2 vectors in non-human primate Schwann cells.
Girard C., Tenenbaum L., Chtarto A., Attali B., Salvetti A., Bachelin C., Evercooren A.B., Lachapelle F., 2005. Neuroreport, 16 (16) pp. 1757-1762.
[WoS][Pmid][serval:BIB_1C48BB938D65]
 
Minocycline in phenotypic models of Huntington's disease.
Bantubungi K., Jacquard C., Greco A., Pintor A., Chtarto A., Tai K., Galas M.C., Tenenbaum L., Déglon N., Popoli P. et al., 2005. Neurobiology of Disease, 18 (1) pp. 206-217. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5C3A4B5F5795]
2004
 
Clinical potential of minocycline for neurodegenerative disorders.
Blum D., Chtarto A., Tenenbaum L., Brotchi J., Levivier M., 2004. Neurobiology of Disease, 17 (3) pp. 359-366. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4E3EBA137A3F]
 
Efficient early and sustained transduction of human fetal mesencephalon using adeno-associated virus type 2 vectors.
Tenenbaum L., Peschanski M., Melas C., Rodesh F., Lehtonen E., Stathopoulos A., Velu T., Brotchi J., Levivier M., 2004. Cell Transplantation, 13 (5) pp. 565-571. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1C95D8A6EC31]
 
Rescue and sprouting of motoneurons following ventral root avulsion and reimplantation combined with intraspinal adeno-associated viral vector-mediated expression of glial cell line-derived neurotrophic factor or brain-derived neurotrophic factor.
Blits B., Carlstedt T.P., Ruitenberg M.J., de Winter F., Hermens W.T., Dijkhuizen P.A., Claasens J.W., Eggers R., van der Sluis R., Tenenbaum L. et al., 2004. Experimental Neurology, 189 (2) pp. 303-316.
[DOI][WoS][Pmid][serval:BIB_B490664FCD1F]
2003
 
Adeno-associated viral vectors.
Lehtonen E., Tenenbaum L., 2003. International Review of Neurobiology, 55 pp. 65-98.
[WoS][Pmid][serval:BIB_67EB8B8B672E]
 
Minocycline-induced activation of tetracycline-responsive promoter.
Chtarto A., Tenenbaum L., Velu T., Brotchi J., Levivier M., Blum D., 2003. Neuroscience Letters, 352 (3) pp. 155-158. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7609B9070C7F]
 
Tetracycline-inducible transgene expression mediated by a single AAV vector.
Chtarto A., Bender H.U., Hanemann C.O., Kemp T., Lehtonen E., Levivier M., Brotchi J., Velu T., Tenenbaum L., 2003. Gene Therapy, 10 (1) pp. 84-94. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_19117154A560]
2002
 
AAV2 vectors mediate efficient and sustained transduction of rat embryonic ventral mesencephalon.
Lehtonen E., Bonnaud F., Melas C., Lubansu A., Malgrange B., Chtarto A., Velu T., Brotchi J., Levivier M., Peschanski M. et al., 2002. Neuroreport, 13 (12) pp. 1503-1507. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F191385246F5]
 
La Clinique d'Oncologie Médicale [The medical oncology clinic].
Velu T., Brandenburger A., Bruyns C., Gangji D., Tenenbaum L., 2002. Revue Médicale De Bruxelles, 23 (Suppl 2) pp. 131-136.
[Pmid][serval:BIB_A79CB16DF521]
 
Neuroprotective gene therapy for Parkinson's disease.
Tenenbaum L., Chtarto A., Lehtonen E., Blum D., Baekelandt V., Velu T., Brotchi J., Levivier M., 2002. Current Gene Therapy, 2 (4) pp. 451-483. Peer-reviewed.
[Pmid][serval:BIB_C359A37C80BD]
2000
 
Tropism of AAV-2 vectors for neurons of the globus pallidus.
Tenenbaum L., Jurysta F., Stathopoulos A., Puschban Z., Melas C., Hermens W.T., Verhaagen J., Pichon B., Velu T., Levivier M., 2000. Neuroreport, 11 (10) pp. 2277-2283. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_32C9C43254C2]
1999
 
Cellular contaminants of adeno-associated virus vector stocks can enhance transduction.
Tenenbaum L., Hamdane M., Pouzet M., Avalosse B., Stathopoulos A., Jurysta F., Rosenbaum C., Hanemann C.O., Levivier M., Velu T., 1999. Gene Therapy, 6 (6) pp. 1045-1053. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0BC32567DBD4]
1996
 
Gene delivery using adeno-associated virus
Tenenbaum L., Hooghe-Peters E., 1996. pp. 73-97 dans Lachtman D.S. (eds.) Genetic manipulation of the nervous system chap. 5, Academic Press.
[DOI][serval:BIB_6F8DB2BDC030]
 
Plastic phenotype of human oligodendroglial tumour cells in vitro.
Tenenbaum L., Teugels E., Dogusan Z., Avellana-Adalid V., Hooghe-Peters E.L., 1996. Neuropathology and Applied Neurobiology, 22 (4) pp. 302-310.
[WoS][Pmid][serval:BIB_C609F2629B67]
1994
 
Adeno-associated virus (AAV) as a vector for gene transfer into glial cells of the human central nervous system.
Tenenbaum L., Darling J.L., Hooghe-Peters E., 1994. Gene Therapy, 1 (Suppl 1) pp. S80.
[Pmid][serval:BIB_96F03E3C4643]
 
Use of an autonomous parvovirus vector for selective transfer of a foreign gene into transformed human cells of different tissue origins and its expression therein.
Dupont F., Tenenbaum L., Guo L.P., Spegelaere P., Zeicher M., Rommelaere J., 1994. Journal of Virology, 68 (3) pp. 1397-1406.
[WoS][Pmid][serval:BIB_D89F1852401E]
1993
 
Inhibition of heterologous DNA replication by the MVMp nonstructural NS-1 protein: identification of a target sequence.
Tenenbaum L., Dupont F., Spegelaere P., Zentilin L., Norio P., Giacca M., Riva S., Falaschi A., Rommelaere J., 1993. Virology, 197 (2) pp. 630-641.
[DOI][WoS][Pmid][serval:BIB_6D91C79584DA]
1990
 
Genotoxic potency of monofunctional alkylating agents in E. coli: comparison with carcinogenic potency in rodents.
Quinto I., Tenenbaum L., Radman M., 1990. Mutation Research, 228 (2) pp. 177-185.
[WoS][Pmid][serval:BIB_B305387A0E39]
1988
 
Quantification of the genotoxic effects of alkylating agents in bacterial assays.
Tenenbaum L., Malaveille C., 1988. Mutagenesis, 3 (4) pp. 317-322.
[WoS][Pmid][serval:BIB_C222BCD69D9B]
 
The E. coli multitest: a set of strains to characterize diverse genotoxic effects.
Tenenbaum L., Quinto I., Faelen M., 1988. Mutation Research, 203 (6) pp. 415-426.
[WoS][Pmid][serval:BIB_4EBE42EA68E2]
1985
 
A system for detection of genetic and epigenetic alterations in Escherichia coli induced by DNA-damaging agents.
Toman Z., Dambly-Chaudière C., Tenenbaum L., Radman M., 1985. Journal of Molecular Biology, 186 (1) pp. 97-105.
[WoS][Pmid][serval:BIB_3BE2BF88A0C5]
 
recA-independent mutagenicity induced by chloroethylene oxide in E. coli.
Barbin A., Tenenbaum L., Toman Z., Radman M., Bartsch H., 1985. Mutation Research, 152 (2-3) pp. 157-159.
[WoS][Pmid][serval:BIB_F82935707785]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University